Trial Profile
A Phase II Study of a Selective Estrogen Receptor Modulator (LY353381) [arzoxifine] vs. Tamoxifen vs. Placebo in Premenopausal Women With an Increased Risk for Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Arzoxifene (Primary) ; Tamoxifen
- Indications Breast cancer
- Focus Biomarker; Therapeutic Use
- 25 Oct 2006 New trial record.